Case 2: Long-Term BRAF/MEK Data in Melanoma

Case 2: Long-Term BRAF/MEK Data in Melanoma

Publication date: Dec 02, 2019

A review of the data supporting BRAF/MEK inhibition for patients with metastatic melanoma and a BRAF V600E mutation.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Concepts Keywords
Air Immunotherapy
Aluminum Tumor
Ankara Low overburden law
Antibodies Medicine
Balloon Clinical medicine
BRAF RTT
Clinical Trial Melanoma
Columbus Cancer treatments
Dakar Antineoplastic drugs
Deborah Raffin Targeted therapy
Fermented BRAF
Finn Checkpoint inhibitor
Immunotherapy Vemurafenib
Inhibitor Cancer immunotherapy
ISI Http
Kobe Antibodies
Mab
Mabon
Mecca
Mechanization
MEK
Melanoma
Menton
Metastatic
Mono
Mutant
Mutation
Nevel
Nib
Nipple
Oakland
Outline
Overburden
Pemberley
Placebo
Targeted Therapies
Targeted Therapy
Tumor
UNWRA
Virus

Semantics

Type Source Name
disease MESH Melanoma
pathway KEGG Melanoma
drug DRUGBANK Coenzyme M

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *